263 related articles for article (PubMed ID: 27246982)
1. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract][Full Text] [Related]
2. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
3. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.
Esber N; Le Billan F; Resche-Rigon M; Loosfelt H; Lombès M; Chabbert-Buffet N
PLoS One; 2015; 10(10):e0140795. PubMed ID: 26474308
[TBL] [Abstract][Full Text] [Related]
5. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Poole AJ; Li Y; Kim Y; Lin SC; Lee WH; Lee EY
Science; 2006 Dec; 314(5804):1467-70. PubMed ID: 17138902
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal acetate does not impact human normal breast tissue.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Dumont S; Chaouat M; Forgez P; Gompel A
Hum Reprod; 2012 Sep; 27(9):2785-98. PubMed ID: 22740493
[TBL] [Abstract][Full Text] [Related]
8. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.
Calvo V; Beato M
Cancer Res; 2011 May; 71(9):3422-31. PubMed ID: 21531767
[TBL] [Abstract][Full Text] [Related]
11. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
van de Ven M; Liu X; van der Burg E; Klarenbeek S; Alexi X; Zwart W; Dijcks F; Bouwman P; Jonkers J
J Pathol; 2018 Sep; 246(1):41-53. PubMed ID: 29877575
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 mutation influences progesterone response in human benign mammary organoids.
Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
[TBL] [Abstract][Full Text] [Related]
13. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Lee O; Choi MR; Christov K; Ivancic D; Khan SA
Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
[TBL] [Abstract][Full Text] [Related]
15. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.
Esber N; Cherbonnier C; Resche-Rigon M; Hamze A; Alami M; Fagart J; Loosfelt H; Lombès M; Chabbert-Buffet N
Horm Cancer; 2016 Apr; 7(2):137-47. PubMed ID: 26941094
[TBL] [Abstract][Full Text] [Related]
17. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE; Evans I; Jones A; Barrett JE; Haran S; Reisel D; Papaikonomou K; Jones L; Herzog C; Pashayan N; Simões BM; Clarke RB; Evans DG; Ghezelayagh TS; Ponandai-Srinivasan S; Boggavarapu NR; Lalitkumar PG; Howell SJ; Risques RA; Rådestad AF; Dubeau L; Gemzell-Danielsson K; Widschwendter M
Genome Med; 2022 Jun; 14(1):64. PubMed ID: 35701800
[TBL] [Abstract][Full Text] [Related]
18. Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition.
Dobricić J; Branković-Magić M; Filipović S; Radulović S
Cancer Genet Cytogenet; 2010 Oct; 202(1):27-32. PubMed ID: 20804917
[TBL] [Abstract][Full Text] [Related]
19. Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones.
Lee EY
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):68-73. PubMed ID: 18197009
[TBL] [Abstract][Full Text] [Related]
20. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.
McFall T; Patki M; Rosati R; Ratnam M
Oncotarget; 2015 Oct; 6(32):33146-64. PubMed ID: 26356672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
